Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2021-08-15
Target enrollment:
Participant gender:
Summary
This study is investigating the combination of Brentuximab vedotin and lenalidomide in the
treatment of relapsed/refractory peripheral T cell lymphoma or cutaneous T cell lymphoma or
Hodgkin lymphoma.
It is hypothesised that lenalidomide may augment the actions of Brentuximab vedotin in these
patient groups. The primary objective of the study is to determine the maximum tolerated dose
of the combination treatment, which can be used in subsequent studies. The study will also
investigate disease response and survival.
Participants will receive Brentuximab vedotin (once every 21 days i.e. 1 cycle) and
lenalidomide (daily from day 1 -14 of each cycle) for a maximum of 48 weeks and will be
followed for a subsequent 6 months after the end of treatment.